Clinical Trial Update: A Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the combination of temsirolimus (Torisel) and pegylated liposomal doxorubicin (Doxil/Caelyx) in advanced or recurrent breast, endometri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Endometrial Cancer
• Ovarian Cancer

Drugs mentioned

• Doxil (liposomal doxorubicin)
• Torisel (Temsirolimus)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Advanced/Recurrent Breast Cancer, Endometrial Cancer | Phase 1 | Status: UNKNOWN